Tirzepatide for
Weight Management and Glycemic Control
Tirzepatide (Mounjaro®) is the first dual receptor agonist that acts on both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).
When combined with diet and exercise, it can be used for:
-
Type 2 diabetes: in patients with inadequate glycemic control
-
Chronic weight management:
-
Adults with obesity (BMI ≥ 30); or
-
Adults who are overweight (BMI ≥ 27) with at least one weight-related condition (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease)
-
Available doses*: 2.5 mg / 5 mg / 7.5 mg / 10 mg
Administration: Subcutaneous injection, once weekly
* Dosage must be determined and adjusted by a registered doctor based on individual factors such as tolerance, glycemic control, and weight-management goals.
Improvements in Key Parameters From Baseline to 72 Weeks*:
Body Weight: Average reduction of 16.0% to 22.5%
Visceral Fat: Average reduction of 40.1%
Waist Circumference: Reduction of 14.6 to 19.9cm
Systolic Blood Pressure: Reduction of 7.0 to 8.2 mmHg
Diastolic Blood Pressure: Reduction of 4.6 to 5.5mmHg
Triglycerides: Reduction of 24.3% to 31.4%
HDL Cholesterol: Improvement of 7.0% to 8.6%
LDL Cholesterol: Reduction of 5.3% to 8.6%
* Data provided by Eli Lilly Asia. For reference only; individual results may vary.
Mechanism of Action
GLP-1 (Glucagon-Like Peptide-1)
-
Slows gastric emptying and enhances satiety
-
Stimulates insulin secretion while suppressing glucagon, helps reduce blood glucose levels
-
Supports appetite control and caloric management
GIP (Glucose-Dependent Insulinotropic Polypeptide)
-
Stimulates insulin secretion in response to food intake
-
Acts on adipocytes, reducing the tendency for fat storage
By simultaneously acting on both GIP and GLP-1 incretin receptors, tirzepatide provides multiple metabolic benefits:
Glycemic regulation
-
Improves insulin sensitivity, contributing to more stable blood glucose control.
Appetite control
-
Reduces food cravings and overall caloric intake, supporting weight management.
Prolonged satiety
-
Slows gastric emptying, allowing food to remain in the stomach longer; extends the feeling of fullness and helps prevent overeating.
Improved energy metabolism
-
Regulates energy storage and utilization; may help reduce visceral fat accumulation, improve waist circumference, and enhance overall metabolic health.
Potential side effects
During treatment with tirzepatide (Mounjaro®), some individuals may experience gastrointestinal discomfort such as nausea, diarrhea, decreased appetite, vomiting, constipation, or abdominal pain. These reactions are generally mild to moderate and often diminish over time.
Treatments must be preceded by a professional evaluation conducted by a registered medical doctor based on the individual’s health condition. Dosage and number of sessions will be tailored according to each patient’s specific needs.
All treatments and medications at our centre require an in-person consultation and professional evaluation by a registered doctor before prescription.